David Z.I. Cherney - Publications, H-index & Citations

David Z.I. Cherney

University Health Network

76H指数

569论文数

2.6W被引数

收录论文 292

发表时间

Effects of semaglutide on kidney disease in type 2 diabetes: a randomized placebo-controlled trial 司美格鲁肽对2型糖尿病肾脏疾病的影响：一项随机安慰剂对照试验

Nature Medicine

IF50

2026-10-01

OAAI

Katherine R. Tuttle; Petter Bjornstad; Cathy Smith; Menno Pruijm; Phillip J. McCown; Jeffrey B. Hodgin; David Z. I. Cherney; Nicolas Belmar; Milenta Mariam Chacko; Vivek Das; Thomas P. Gunnarsson; Thomas Idorn; Philip A. Schytz; Amaya Zaratiegui; Matthias Kretzler

Acute eGFR Changes With Finerenone Examined in a Prespecified Analysis of FINE-ONE 在FINE-ONE研究的预设分析中考察非奈利酮引起的急性eGFR变化

Kidney International Reports

IF5.7

2026-09-16

OAAI

David Z.I. Cherney; Tae Won Yi; Hiddo J.L. Heerspink; Linong Ji; Janet B. McGill; Peter Rossing; Katherine R. Tuttle; Jesper N. Bech; Paolo Fiorina; Albert Power; Karoline Schousboe; Nicholas M. Selby; Emanuela Setola; J. David Smeijer; Robert Lawatscheck; Meike Brinker; Julie Russell; Patrick Schloemer; Per-Henrik Groop

Metabolic Pathway Signatures of Amino Acids Across the Spectrum of Dialysis-Associated Fatigue 氨基酸代谢通路特征在透析相关疲劳谱系中的表现

Journal of Renal Nutrition

IF3.2

2026-09-08

PREAI

Luxcia Kugathasan; Vikas S. Sridhar; Nagarjunachary Ragi; Swetha Rani Kanduri; Ethan J. Parikh; Ethan A. Jackson; Carlos Lorenzo; Kumar Sharma; David Z.I. Cherney; Subrata Debnath

Finerenone in hypertensive non-diabetic chronic kidney disease: a FIND-CKD subgroup analysis 非糖尿病性高血压慢性肾脏病患者中的非奈利酮：FIND-CKD亚组分析

European Heart Journal

IF35.6

2026-08-30

OAAI

Hiddo J L Heerspink, PhD; Jelle M Beernink, MD; Rajiv Agarwal, MD; David Z I Cherney, MD, PhD; Carolyn S P Lam, MB, BS, PhD; Brendon L Neuen, MB, BS, PhD; Vlado Perkovic, MB, BS, PhD; Katherine R Tuttle, MD; Pantelis Sarafidis, MD, MSC, PhD; Rita Birne, MD; Xiangmei Chen, MBBS, PhD; Mads Hornum, MD, PhD; Rafael A Maldonado, MD; Masaomi Nangaku, MD, PhD; Susanne B Nicholas, MD, MPH, PhD; Atsuki Ohashi, MD; Pablo E Pergola, MD, PhD; See Cheng Yeo, MMed; Niels Jongs, PhD; J David Smeijer, MD; Carolina Aldworth, MD, MSc, MBA; Meike Brinker, MD; Peter Kolkhof, PhD; Juliana D Reis, MSc; Andrea Scalise, MD; Christoph Wanner, MD; null

Effect of Sotagliflozin on Kidney Function and Cardio-Kidney-Metabolic Parameters Across Baseline eGFR Subgroups in Patients With Type 2 Diabetes and Stage 4 CKD sotagliflozin对伴有4期CKD的2型糖尿病患者肾脏功能及心肾代谢参数的影响：基于基线eGFR亚组分析

DIABETES OBESITY & METABOLISM

IF5.7

2026-08-28

OAAI

Vikas S. Sridhar; Luxcia Kugathasan; Manon Girard; Michael J. Davies; David Z. I. Cherney

The Impact of Kidney Function on Diabetic Ketoacidosis and Severe Hypoglycemia Among Adults With Type 1 Diabetes: Insights From the T1D Exchange Real-World Observation Study 肾功能对1型糖尿病成人患者糖尿病酮症酸中毒和严重低血糖的影响：来自T1D Exchange真实世界观察研究的研究启示

DIABETES OBESITY & METABOLISM

IF5.7

2026-08-11

PREAI

Tae Won Yi; Slaven Sikirica; Saketh Rompicherla; Susan Thapa; Michael Davies; Francesco Vendrame; David Lam; Nirali Shah; Guillermo Umpierrez; Osagie Ebekozien; Bruce A. Perkins; David Z. I. Cherney

Effects of Vicadrostat/Empagliflozin in People With Chronic Kidney Disease: Metabolic Subgroup Analyses 维卡多司他/恩格列净对慢性肾脏病患者的影响：代谢亚组分析

diabetes, obesity and metabolism

IF0

2026-05-05

OAAI

David Z. I. Cherney; Peter Rossing; Maria Eugenia Canziani; Maria Luiza Caramori; Ricardo Correa-Rotter; Lisa Cronin; Christian Hugo; Bo Ji; Juliane Meyerhoff; Masaomi Nangaku; Arnold Silva; Dorothea Urbach; Shimoli V. Shah; Dick de Zeeuw; Katherine R. Tuttle

WCN26-3792 Mechanistic Kidney Effects of Semaglutide by Baseline SGLT2i Use in Type 2 Diabetes: A Post-hoc Analysis of the REMODEL Trial WCN26-3792 基线SGLT2i使用对司美格鲁肽在2型糖尿病中肾脏机制效应的影响：一项REMODEL试验的事后分析

Kidney International Reports

IF5.7

2026-05-04

OAAI

David Cherney; Radica Alicic; Milenta Chacko; Lynette Driscoll; Emma Olesen; Prachi Priyadarshini; Vikas Sridhar; Katherine Tuttle; Petter Bjornstad

Acute Estimated Glomerular Filtration Rate Decline After Initiation of Therapies That Slow Kidney Disease Progression: Clinical Practice Implications 急性估算肾小球滤过率下降与延缓肾脏疾病进展疗法的启动：临床实践意义

Mayo Clinic Proceedings

IF6.7

2026-04-21

OAAI

David Z.I. Cherney; Radica Z. Alicic; Marc P. Bonaca

Association of Ertugliflozin on Kidney Outcomes in People After and Without an Interval Cardiovascular Event: Observations From the VERTIS CV Trial ERTUGLIFLOZIN对有和无间隔心血管事件人群肾脏结局的影响：VERTIS CV试验的观察

American Journal of Kidney Diseases

IF8.2

2026-04-21

PREAI

Ayodele Odutayo; Francesco Cosentino; Richard E. Pratley; Christopher P. Cannon; Chih-Chin Liu; Robert Frederich; Urszula Masiukiewicz; Nilo B. Cater; Ira Gantz; David Z.I. Cherney

Renal functional reserve predicts GFR response to empagliflozin in RENALIS and RACELINES clinical trials 肾功能储备预测恩格列净在RENALIS和RACELINES临床试验中对GFR的反应

Nephrology Dialysis Transplantation

IF5.6

2026-04-01

PREAI

van Baar, Michael J. B.; Bjornstad, Petter; Touw, Daan J.; Joles, Jaap A.; Krebber, Merle M.; Cherney, David Z., I; van Raalte, Daniel H.; Muskiet, Marcel H. A.

Semaglutide and cardiovascular risk in type 1 diabetes: A predictive modelling analysis in a double-blind, randomised, placebo-controlled cross-over trial

diabetes, obesity and metabolism

IF0

2026-02-02

OAAI

Luxcia Kugathasan PhD; Michael A. Tsoukas MD; Massimo Nardone PhD; Vikas S. Sridhar MD; Marcel H. A. Muskiet MD; David Z. I. Cherney MD; Ahmad Haidar PhD; Melissa-Rosina Pasqua MD

Cardiovascular-Kidney Effects of Dapagliflozin in Patients at Cardiovascular Risk With or Without Type 2 Diabetes: Results of a Randomized, Double-Blind, Placebo-Controlled Trial 达格列净在心血管风险患者（无论是否患有2型糖尿病）中的心血管-肾脏效应：一项随机、双盲、安慰剂对照试验的结果

Hypertension

IF8.2

2026-02-01

PREAI

Sridhar, Vikas S.; Kugathasan, Luxcia; Lytvyn, Yuliya; Deng, Yangqing; Liu, Hongyan; Lovblom, Leif Erik; Tse, Josephine; Nardone, Massimo; Floras, John S.; Osuntokun, Tosin; Tobushi, Tomoyuki; Lam, Ruthabella C. Y.; Lam, Brian; Stevens, Jasper; Burger, Dylan; Touw, Daan J.; Heerspink, Hiddo J. L.; Lovshin, Julie A.; Perkins, Bruce A.; Cherney, David Z. I.

Effects of sotagliflozin on markers of volume status and sodium handling in patients with type 1 diabetes: A biomarker analysis of the inTandem3 clinical trial

diabetes, obesity and metabolism

IF0

2026-01-27

OAAI

Massimo Nardone PhD; Erik Moedt MSc; Hiddo J. L. Heerspink PhD; Michael J. Davies PhD; Manon Girard MSc; David Z. I. Cherney MD; Marcel H. A. Muskiet MD

Next-generation therapeutics for diabetic kidney disease 糖尿病肾病的下一代疗法

Nature Reviews Nephrology

IF39.8

2026-01-12

PREAI

Tae Won Yi; Vikas S. Sridhar; Jennifer Scott; Massimo Nardone; David Cherney

The Role of Inflammation and High-Sensitivity C-Reactive Protein in Atherosclerotic Cardiovascular Disease and Chronic Kidney Disease: The FLAME-ASCVD Survey among Nephrologists 炎症和高敏C反应蛋白在动脉粥样硬化性心血管疾病和慢性肾脏病中的作用：肾科医生参与的FLAME-ASCVD调查

Cardiorenal Medicine

IF2.9

2026-01-01

OAAI

Perkovic, Vlado; Cherney, David; Erazo-Tapia, Edmundo; Gerward, Sofia; Waechter, Sandra; Sahay, Manisha; Marx, Nikolaus

Chronic kidney disease screening to reduce cardiovascular risk: a call to action 慢性肾脏疾病筛查降低心血管风险: 行动呼吁

American Journal of Preventive Cardiology

IF5.9

2025-12-11

OAAI

Erin D. Michos; David Cherney; Pam Kushner

Efficacy, Mechanisms, and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Kidney Transplant Recipients 钠-葡萄糖协同转运蛋白-2抑制剂在肾移植受者中的疗效、机制与安全性：一项随机、双盲、安慰剂对照试验

CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

IF7.1

2025-12-01

PREAI

Sridhar, Vikas S.; Kugathasan, Luxcia; Lytvyn, Yuliya; Liu, Hongyan; Deng, Yangqing; Lovblom, Leif Erik; Nardone, Massimo; Yuen, Darren A.; Chen, Yixiao; Hua, Jonathan; Aronson, Yarden; Mohsen, Mai; Kim, S. Joseph; Udell, Jacob A.; Perkins, Bruce A.; Stevens, Jasper; Touw, Daan J.; Heerspink, Hiddo J. L.; Cherney, David Z. I.; Singh, Sunita K. S.

Glucagon-like Peptide-1 Receptor Agonists and Risk of Major Adverse Cardiovascular Events in Patients With CKD 胰高血糖素样肽-1受体激动剂与慢性肾病患者的重大心血管不良事件风险

American Journal of Kidney Diseases

IF8.2

2025-11-12

OAAI

Kevin Yau; Joel G. Ray; Nivethika Jeyakumar; Bin Luo; Sheikh Abdullah; Stephanie N. Dixon; Sara Wing; Kristin K. Clemens; Fabio Castrillon-Ramirez; Jacob A. Udell; Alejandro Meraz-Munoz; Ann Young; Ziv Harel; Jeffrey Perl; Lawrence A. Leiter; Amit X. Garg; David Z.I. Cherney; Ron Wald

REMODELing Mechanistic Trials for Kidney Disease: a multi-modal, tissue-centered approach to understand the renal mechanism of action of semaglutide REMODELing机制试验用于肾脏疾病：一种多模态、组织中心化的方法，用于理解semaglutide的肾脏作用机制

Kidney International

IF12.6

2025-11-07

OAAI

Menno Pruijm; Nicolas Belmar; Petter Bjornstad; David Z.I. Cherney; Vivek Das; Thomas Gunnarsson; Jeffrey B. Hodgin; Philip A. Schytz; Katherine R. Tuttle; Matthias Kretzler

研究方向